Clinical Neurology and Neuroscience
Volume 4, Issue 4, December 2020, Pages: 71-75
Received: Sep. 26, 2020;
Accepted: Oct. 13, 2020;
Published: Oct. 21, 2020
Views 190 Downloads 59
Mitalip Mamytov, Department of Neurosurgery, Kyrgyz State Medical Academy, Kyrgyzstan, Bishkek
Background: The cells of the immune system are actively involved in the tumor development process and can either suppress or stimulate tumor growth. Objective: to determine the role and significance of immunological indications of patients with brain tumors of different histostructure before and after surgical treatment. Methods: The number of lymphocytes, neutrophilic granulocytes, and platelets was analyzed in 246 patients with brain tumors of various histostructures. Results: It was determined that there were significant fluctuations in the content of leukocytes in the blood of patients with brain tumors of various histogenesis. The largest number of leukocytes was observed in neuroectodermal and mesenchymal tumors. However, neuroepithelial tumors (pituitary adenomas) did not show a considerable increase in the number of leukocytes compared with that in healthy individuals. Conclusions: It is revealed that the determination of the immune response is an essential component of clinical examination. These immune response options allow to develop targeted immunotherapy. The determination of immunoreactivity for these options was determined to be clinically feasible. In addition, belonging to a particular group based on the immune status considerably determines the further course of the tumor process and the effectiveness of the surgical treatment of brain tumors.
Immunoreactivity of the Body During the Surgical Treatment of Brain Tumors, Clinical Neurology and Neuroscience.
Vol. 4, No. 4,
2020, pp. 71-75.
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/
) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Kim J, Bal JS (2016) Tumor-Associated Macrophages and neutrophils in tumor microenvironment. Mediatorainflamm. 6058147. Pubmedpmia: 26966341.
Lisyanyi NI (2014) The content of oncogenic viruses in medulloblastomas and gliomas of the brain. Materials of the international scientific-practical conference. Kiev: 34-36.
Lisyanyi NI (1990) The effect of surgery on the immune system upon brain tumors. Clinical surgery 12: 4-6.
Menter DY, Tucker SC, Kopetz S. et al. (2014) Platelets and cancer: a casual or causal relationship: Revisiter. Cancer Metastasis Rev 33 (1): 231–269.
Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170 (5): 1445-1453.
Waziri A (2010) Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin N Am 21 (1): 31-42.
Auezova A et al. (2016) Association of preoperative levels of selected blood inflammatory markers with prognosis in Gliomas. Oncotargetsther 11 (9): 6111-6117.
Wang Q. et al. (2017) Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 32: 42–56 e46.
Woroniecka KI, Rhodin KE, Chongsathidkiet P, Keith KA, Fecci PE. (2018) T-cell dysfunction in glioblastoma: applying a new framework. Clin. Cancer Res. 24: 3792–3802.
Aquino D, Gioppo A, Finocchiaro G, Bruzzone MG, Cuccarini V. (2017) MRI in glioma immunotherapy: evidence, pitfalls, and perspectives. J. Immunol. Res. 5813951.
Wu A et al. (2019) Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment. J. Neurooncol. 143: 241–249.
Sampson JH, Gunn MD, Fecci PE, Ashley DM (2019) Brain immunology and immunotherapy in brain tumours. Nature Reviews Cancer. 20: 12-25.
Starchenko AA (2001) Clinical neuroimmunology of surgical diseases of the brain. SPb.: Saint-Petersburg Medical Ed., p. 324.
Chernyh ER (2002) Combined immunotherapy in the treatment of malignant brain tumors. Medical immunology 4 (4–5): 583-592.
Brandlein S, Pohle T, Ruoff N, Wozniak E, Muller¨Hermelink HK, Vollmers HP (2003) Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res. 63 (22): 7995-8005.
Xu LW, Chow KK, Lim M, Li G (2014) Current vaccine trials in glioblastoma: a review. Journal of immunology research 796856.
Gorbunov VI (1996) Immunopathology of a traumatic disease. Ulyanovsk, SHU: p. 71.
Selyukova MV (2004) Features of the immune status in patients with meningiomas and gliomas of the cerebral hemispheres Author’s thesis, master’s dissertation Kirov: p. 24.
Dix AR, Brooks WH, Roszman TL, Morford LA (1999) Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100: 216–232.
CA J, PT, MW, MS (2001) Immunobiology 5: The Immune System in Health and Disease. 5 ed., New York: Garland Publishers.
Bacic D, Uravic M, Bacic R, Sutic I, Petrosic N (2011) Augmentation of regulatory T cells (CD4+CD25+Foxp3+) correlates with tumor stage in patients with colorectal cancer. Collegium antropologicum 35 Suppl 2: 65-68.
Norden AD, Drappatz J, Wen PY (2008) Novel anti-angiogenic therapies for malignant gliomas. Lancet neurology 7 (12): 1152-1160.
Rudenko VA (1990) Subpopulations of lymphocytes and their functional activity in brain tumors. Medical business 9: 91–94.